Microneedling With Active Acne: Should You Postpone Your Appointment?

The Short Answer

If you have a microneedling appointment or a prepaid package on the calendar and your skin is breaking out, call the clinic before the visit. A cautious default is to postpone until inflammatory lesions have settled, with the treating clinician deciding after examining your skin. That recommendation is an inference from limited treatment evidence, the authorized-use boundary, and screening concerns. The cited studies do not establish a safe waiting interval or prove that every breakout will be harmed by needling.

Start with the authorization boundary. The FDA microneedling devices page, with content current as of October 15, 2025, says the agency has legally authorized microneedling devices to improve the appearance of facial acne scars, facial wrinkles, and abdominal scars in patients aged 22 years or older. Active acne vulgaris is not on that list. A device cleared to improve acne scars is not thereby authorized to treat the breakout itself. The 2023 plain-pen pilot discussed below investigated active acne outside that scar indication. Ask the clinic to explain the proposed use against the exact device labeling; a published study is not a new FDA authorization. RF devices have separate labeling and evidence, discussed later. The FDA page adds that the risks of off-label uses of these devices are not known.

One explanation offered for postponing is that needles could spread acne-associated bacteria and worsen lesions. The 2023 plain-microneedling pilot authors challenged that perception and reported improvement without post-treatment complications. Their study had only 12 completers, no comparison group, and a sponsor that employed every author. It did not establish either that bacterial transfer causes worsening or that needling a breakout is reliably safe. A plausible concern and a small reassuring study still leave uncertainty.

Guideline writers have not filled it either. When the American Academy of Dermatology announced its 2024 acne guideline, it said available evidence was insufficient to develop recommendations for procedures such as chemical peels, laser and light-based devices, and microneedling.

Before the appointment, focus the consultation on these questions: which kinds of lesions are present, whether anything could be an infection or a cold sore, which acne medicines you have taken and when, how your skin tone affects pigment risk, and whether the booking is plain microneedling or RF microneedling. The sections below take those in turn. They are things to raise with a clinician who examines your skin in person. They are not a way to clear yourself for treatment.

What 'Active' Means: Comedones, Papules and Pustules, Nodules

Acne is not a single kind of spot. The 2023 pilot paper uses the standard split: inflammatory lesions are papules, pustules, and nodules, and non-inflammatory lesions are open and closed comedones, often called blackheads and whiteheads. The phrase active breakouts can hide those differences, although they change the questions to raise with the clinician.

The table below sets out what each term means, what the published needling evidence covers for it, and what to raise at the consultation. It is not a treatment rule. Severity is something a clinician grades on examination, and the evidence column shows how little of this ground has been studied.

The most useful line in that table is the one between active infection and active acne inflammation. The FDA list of reasons the procedure may not be suitable names an active skin infection, including bacterial, viral, or fungal infection, an active rash on the face, and a current outbreak of cold sores. Acne is not on the list by name. That does not make inflamed acne safe to needle. It means that postponing for a breakout is a clinical judgment about inflamed skin, while postponing for an infection or a cold sore follows the FDA's own screening language. Clinic copy that calls every pimple an infection blurs the two, and so does copy that treats any breakout as harmless.

One case report in the systematic review discussed below shows why someone other than the patient should look first. A woman who self-treated what appeared to be acne-like eruptions on her chest and face with a home-use roller was later found to have spread varicella, the chickenpox virus, from her chest to her face. The bumps she was needling were not what she thought they were. The FDA consumer update also notes that the agency has not authorized any microneedling medical device for over-the-counter sale.

Where the 'It Spreads Bacteria' Warning Comes From

The 2023 pilot paper states the belief plainly: it is a general perception in the medical community that needling over inflammatory acne lesions could worsen acne by spreading the acne-associated bacterium Cutibacterium acnes from those lesions to other areas of the face. The authors argue that there is no definitive evidence that acne spreads by microbial transfer, and they point out that C. acnes is one of the most abundant bacteria on healthy skin. Those arguments come from authors with a commercial interest in the answer. Their literature-search statement concerned plain microneedling as acne treatment. It should not be read as evidence that RF acne studies did not exist, or that the warning has been disproved.

The broader safety literature is the next place to look. A 2021 systematic review by Gowda and colleagues in the Journal of Clinical and Aesthetic Dermatology covered 51 articles and 1,029 patients treated with roller, stamp, pen, and fractional RF microneedling devices. The authors describe microneedling as relatively safe and say that mild effects such as redness and pain are expected while more severe adverse effects are relatively rare. They identified only two reports of infection, and both involved roller devices. One was the home-use varicella case above. The other was a superficial facial infection that appeared seven days after roller microneedling combined with photodynamic therapy. The review also notes that recurrence or flares of acne are possible in patients treated with roller microneedling for acne scars.

Two infection reports in more than a thousand patients sounds reassuring until you read how the studies were run. The authors say infection may have been rarely reported partly because many studies gave prophylactic or post-procedure antibiotics or antivirals, used inconsistently, which may confound the true infectious potential of microneedling. They also say that active infections are a contraindication to microneedling, so many studies excluded patients with active infections. The two reports are not an infection rate for needling inflamed acne. Excluding active infection does not mean excluding all acne inflammation, and this review also included RF studies treating acne. Its mixed devices, indications, and preventive care cannot give a reliable risk estimate for a plain-pen session during your breakout.

A newer real-world cohort shows the same pattern. In a 2025 cross-sectional study from one hospital in Tehran, Ehsani and colleagues surveyed 120 patients one month after facial microneedling, most of them treated for scars. Hyperpigmentation was reported by 6.7 percent, hypopigmentation by 1.7 percent, persistent redness by 2.5 percent, and itching by 9.2 percent. Every participant reported transient redness, peeling, and dryness, and none reported scar formation or inflammatory acne. But the exclusion criteria barred anyone with active infection or inflammation at the treatment site, topical gentamicin was recommended for three days afterward, and the authors acknowledge in their limitations that they did not record skin phototypes. They note only that most patients at their center are phototypes 3 and 4.

What a Small Non-RF Pilot Can and Cannot Show

A study specifically investigating plain microneedling for active acne is a 2023 pilot by Alqam, Jones, and Hitchcock in Skin Health and Disease. It enrolled 15 people with acne (11 women and 4 men) whose Investigator's Global Assessment (IGA) scores were 1 to 3. People with a score of 4 were excluded, as were those who had used systemic retinoids in the past six months, used topical acne treatments such as anti-inflammatory agents or antibiotics, had recent cosmetic treatments in the area, or were pregnant or nursing. Twelve finished. Two dropped out for non-compliance and one withdrew consent. The 12 completers were aged 18 to 45 and had Fitzpatrick skin types II to IV.

This was a clinician-run research protocol using SkinPen Precision, with papules and pustules treated directly. That detail matters because the investigators were testing active lesions rather than just scars. Nine completers received three sessions four weeks apart; three received four sessions two weeks apart. Everyone had a final assessment two months after the last treatment. These study schedules describe what was tested and are not a treatment plan for readers.

Lesion changes are measured from baseline to the two-month follow-up. IGA is the Investigator's Global Assessment. The authors reported that microneedling did not cause post-treatment complications and that instrument-measured redness did not change in any subject during the study. From this they concluded that there is no scientific reason for microneedling to be contraindicated for acne.

That conclusion goes well past what the study can support:

1. Funding and authorship. The conflict-of-interest statement says all three authors are employees of Crown Laboratories, which funded the study. The pen was the SkinPen Precision from Crown Aesthetics, and subjects were given a skincare regimen from the same Crown Aesthetics product line. The paper states that its data will not be made publicly available.

2. No comparison group. Nobody received standard acne treatment, a sham procedure, or no treatment, and the paper does not describe blinding. Without a comparison, the study cannot show how much of the improvement would have happened anyway.

3. Very small numbers. Twelve people finished, and one arm had three. A study that size can miss uncommon complications entirely, so zero complications in 12 people is not evidence that complications are rare.

4. A narrow population. IGA scores 1 to 3, Fitzpatrick II to IV, ages 18 to 45. Severe-grade acne was excluded. The paper did not report a separate outcome for nodular or cystic acne and cannot establish suitability for Fitzpatrick V and VI skin or for people younger than 18.

5. Short follow-up. The last check was two months after the final session. One Group 2 participant pictured in the paper had relapsed by that visit, after treatment stopped, and the authors say more studies are needed to determine long-term benefit.

RF microneedling has also been studied for active acne, but it is a different procedure. One small example illustrates why that evidence needs separate assessment. A 2023 study by Hasan and colleagues in Postępy Dermatologii i Alergologii followed 40 people with moderate acne at a teaching hospital in Baqubah, Iraq. Twenty received RF microneedling at weeks 0, 4, 8, and 12 alongside oral isotretinoin, and 20 received isotretinoin alone. Both groups improved substantially on the global acne assessment scale. The combination group scored better at 12 weeks and at 6 months, with no difference between groups at 4 and 8 weeks. The authors describe it as a cross-sectional comparative study, do not describe any blinding, photographed patients with a phone camera, and counted lesions by hand. Two further cautions matter for US readers. It used RF microneedling, so its results cannot be borrowed to support a plain microneedling pen. And it needled people while they were taking isotretinoin, and current isotretinoin use is on the FDA microneedling page's list of reasons the procedure may not be suitable.

Check what before-and-after photos actually represent. Scar improvement and control of active breakouts are different outcomes, and a scar study may exclude the skin condition you currently have. For example, a 2025 open-label randomized trial by Al Mallah and colleagues comparing RF microneedling, fractional CO2 laser, and the two in sequence for atrophic acne scars excluded patients with active acne lesions. Photos and results from studies like that are evidence about scars. They are not evidence about needling a flare.

If You Take Isotretinoin: The Six-Month Rule Under Review

If you take oral isotretinoin or recently finished it, disclose that before arranging a procedure. The FDA microneedling devices page lists currently taking isotretinoin (Accutane), or having taken it in the past 6 months, among the reasons the procedure may not be suitable. The 2023 pilot also excluded anyone who had used systemic retinoids in the previous six months.

The research literature questions that window. A 2017 systematic review with consensus recommendations by Spring and colleagues in JAMA Dermatology notes that the belief that isotretinoin taken within 6 to 12 months of a procedure causes abnormal scarring traces back to 3 small case series from the mid-1980s. Reviewing 32 publications that reported 1,485 procedures, the panel found insufficient evidence to support delaying manual dermabrasion, superficial chemical peels, cutaneous surgery, laser hair removal, and fractional ablative and nonablative laser procedures. Mechanical dermabrasion and fully ablative laser were still not recommended during isotretinoin treatment. Microneedling was not one of the review's search terms.

A task force of the Association of Cutaneous Surgeons of India went further in its 2017 standard guidelines. It recommended that microneedling and microdermabrasion can safely be performed in patients on isotretinoin, but that specific recommendation is graded C and rests on two studies. The task force called the original advice to avoid procedures "based on flawed reasoning." It also documents that standard textbooks and the drug's patient information advise waiting six months after stopping isotretinoin before certain procedures.

This is an open disagreement, not a settled update. A US clinic that follows the FDA screening list is not being unreasonable when it asks you to wait. At the same time, the six-month figure is screening guidance, not a law, and the reviews challenging it did not study plain microneedling pens over active acne. Tell both your isotretinoin prescriber and the treating clinician the date of your last dose, and let them make the timing decision together. Our guide to isotretinoin and aesthetic procedures covers the waiting-period evidence across other procedures.

Risks That Apply Either Way: Pigmentation, Cold Sores, Infection, RF Injuries

Postponing does not guarantee a safe later session. Suitability and ordinary procedure risks still need review when the appointment is rescheduled. The FDA device page separates common from less common risks for authorized uses. The table below pairs those with what the reviewed studies add and with what to ask. These are reported events and survey rates from particular groups of patients, not a personal risk estimate.

Pigment change deserves particular attention if you have Fitzpatrick IV to VI skin. The FDA screening list includes having a darker skin type, "as there is a risk of darkening or lightening of the skin after the procedure," and adds that some FDA-authorized devices were not studied in subjects with darker skin types. The direct active-acne pilot enrolled only types II to IV, and the Tehran cohort's limitations acknowledge missing phototype records. The 2021 JCAD review discusses a possible pigment-related advantage for RF microneedling, but its evidence spans different indications and devices. It does not establish a preferred procedure for active acne in Fitzpatrick IV to VI skin, and it predates the FDA’s RF safety communication. Our guides to post-inflammatory hyperpigmentation after procedures and acne scar treatments for skin of color cover the wider picture.

The difference between plain microneedling and RF microneedling matters for this question. The FDA safety communication describes RF microneedling devices as Class II devices cleared through the 510(k) process that deliver radiofrequency energy through an array of microneedles to heat tissue at set depths. On October 15, 2025, the FDA reported serious complications with certain uses of these devices, including burns, scarring, fat loss, disfigurement, and nerve damage, and said that RF microneedling is a medical procedure and the devices should not be used at home. The only RF study of active acne in this article combined it with isotretinoin outside the US. Do not assume that the evidence for a plain pen covers an RF appointment, or the reverse. Our explainers on plain versus RF microneedling and the RF microneedling FDA warning go further.

A Consultation Path, Not a Self-Clearance Test

The diagram below maps the conversation to have when a breakout lands before a booked appointment. Every branch ends with a clinician deciding after an examination. None of it sets a needle depth, a technique, or a medicine, and none of it means you can decide on your own that your skin is ready.

flowchart TD
  A["Breakout before a booked microneedling visit"] --> B["Contact the clinic before treatment"]
  B --> C{"Possible infection, new rash, or cold sore?"}
  C -->|Yes or unsure| D["Report it and arrange clinical assessment before any procedure"]
  C -->|No| E{"Isotretinoin now or in the past 6 months?"}
  E -->|Yes| F["Prescriber and treating clinician review timing together"]
  E -->|No| G["Clinician examines lesion types and reviews other screening factors"]
  G --> H{"Inflammatory lesions present?"}
  H -->|Yes| I["Discuss postponement and acne treatment"]
  H -->|Comedones only| J["Discuss the limited plain-pen evidence and exact device labeling"]
  D --> K["Treating clinician decides suitability after assessment"]
  F --> K
  I --> K
  J --> K
  K --> L["Continue clinician-directed acne care while timing is resolved"]

Two branches deserve a word. The comedones-only branch is the one where reasonable clinicians may differ, because the cited plain-pen evidence is small and uncontrolled, and the FDA list does not address comedones specifically. Ask what the decision is based on. The final step applies to everyone. Postponing a device session should not mean pausing acne care, and if a prepaid package is involved, our guide to package terms when you turn out not to be a suitable candidate covers the questions to ask about rescheduling.

What to Ask Before Keeping or Moving the Appointment

A short call before the visit can tell you a lot about how a practice screens patients. These questions are drawn from the FDA's recommendations for patients and providers and from the evidence above:

1. "Will a clinician examine my skin before the session, and what is your policy for inflamed acne?" Ask what the policy is based on: the device's labeling, the FDA screening list, or the clinic's own experience. A policy that can be explained is a better sign than one that cannot. If the clinic offers a plain pen cleared for scars as active-acne treatment, ask it to explain the off-label use and the evidence it relies on. For RF, ask for that device’s indication and patient labeling separately.

2. "Which device will you use, is it FDA-authorized, and is it plain or RF microneedling?" The FDA tells providers to check that a device is listed in its De Novo or 510(k) databases and warns that several microneedling devices are not legally marketed. It also tells patients to ask for the patient labeling that comes with FDA-authorized devices. Our comparison of FDA-cleared powered microneedling devices explains what to look for.

3. "Is a new needle cartridge used for me, for this session?" The FDA consumer update says re-using cartridges can cause or spread infection, and it tells patients to ask how the device is cleaned between patients. Our guide to cartridge sterility questions goes into more detail.

4. "How do you handle a cold-sore history and pigment risk for my skin type?" The FDA tells providers to consider preventive antivirals for patients with a history of herpes simplex, and it warns that some authorized devices were not studied in darker skin types. Whether you need preventive medicine is a prescriber's decision, not something to arrange yourself.

5. "What should my acne treatment be in the meantime?" The 2024 AAD guideline makes strong recommendations for benzoyl peroxide, topical retinoids, topical antibiotics, and oral doxycycline. It strongly recommends oral isotretinoin for acne that is severe, causes psychosocial burden or scarring, or has not responded to standard oral or topical therapy. It makes conditional recommendations for topical clascoterone, salicylic acid, and azelaic acid, and for oral minocycline, sarecycline, combined oral contraceptive pills, and spironolactone. Which of these fits is for a prescriber to decide. Our acne treatment evidence ladder explains how they compare.

Before the call, write down what to tell the clinic: which kinds of spots you have now (blackheads and whiteheads, red or pus-filled bumps, or deep painful lumps), any cold sores or other recent rashes, every acne medicine with dates (including antibiotics and isotretinoin), your skin type and any history of dark marks after spots heal, and any history of keloids, which our keloid screening guide covers. If you are weighing a peel instead, the same timing questions apply differently. Our guide to chemical peels with active acne covers that decision.

Sources

1. U.S. Food and Drug Administration. Microneedling Devices. Content current as of October 15, 2025. Accessed October 5, 2026. https://www.fda.gov/medical-devices/aesthetic-cosmetic-devices/microneedling-devices

2. U.S. Food and Drug Administration. Microneedling Devices: Getting to the Point on Benefits, Risks and Safety. Consumer update, content current as of October 15, 2025. Accessed October 5, 2026. https://www.fda.gov/consumers/consumer-updates/microneedling-devices-getting-point-benefits-risks-and-safety

3. U.S. Food and Drug Administration. Potential Risks with Certain Uses of Radiofrequency (RF) Microneedling. FDA safety communication, issued October 15, 2025. Accessed October 5, 2026. https://www.fda.gov/medical-devices/safety-communications/potential-risks-certain-uses-radiofrequency-rf-microneedling-fda-safety-communication

4. American Academy of Dermatology. American Academy of Dermatology issues updated guidelines for the management of acne. News release, January 31, 2024. Accessed October 5, 2026. https://www.aad.org/news/updated-guidelines-acne-management

5. Reynolds RV, Yeung H, Cheng CE, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2024;90(5):1006.e1-1006.e30. doi:10.1016/j.jaad.2023.12.017. Accessed October 5, 2026. https://pubmed.ncbi.nlm.nih.gov/38300170/

6. Alqam ML, Jones BC, Hitchcock TM. Study to determine the safety and efficacy of microneedling as an effective treatment for acne vulgaris. Skin Health Dis. 2023;3(5):e264. doi:10.1002/ski2.264. Accessed October 5, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC10549865/

7. Gowda A, Healey B, Ezaldein H, Merati M. A Systematic Review Examining the Potential Adverse Effects of Microneedling. J Clin Aesthet Dermatol. 2021;14(1):45-54. Accessed October 5, 2026. https://jcadonline.com/examining-potential-adverse-effects-microneedling

8. Ehsani A, Razavi Z, Mohammadi D, et al. Microneedling side effects and complications: a cross-sectional study. Iran J Dermatol. 2025;28(3):140-145. doi:10.22034/ijd.2024.478946.1902. Accessed October 5, 2026. https://www.iranjd.ir/article_227020.html

9. Hasan IA, Mahdi ZN, Obeed RK. Evaluation of the efficacy of RF microneedling and oral isotretinoin in comparison with oral isotretinoin alone in the treatment of acne vulgaris. Postepy Dermatol Alergol. 2023;40(1):111-114. doi:10.5114/ada.2022.124109. Accessed October 5, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC9993193/

10. Spring LK, Krakowski AC, Alam M, et al. Isotretinoin and Timing of Procedural Interventions: A Systematic Review With Consensus Recommendations. JAMA Dermatol. 2017;153(8):802-809. doi:10.1001/jamadermatol.2017.2077. Accessed October 5, 2026. https://jamanetwork.com/journals/jamadermatology/article-abstract/2632046

11. Mysore V, Mahadevappa OH, Barua S, et al. Standard Guidelines of Care: Performing Procedures in Patients on or Recently Administered with Isotretinoin. J Cutan Aesthet Surg. 2017;10(4):186-194. doi:10.4103/JCAS.JCAS_110_17. Accessed October 5, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC5820835/

12. Al Mallah MN, Abdulqader MN, Al Chalabi QS, Fathi HB. Atrophic Acne Scars Treated With Microneedling Radiofrequency Followed by Fractional CO2 Laser Compared With Each Monotherapy: An Open-Label Randomized Controlled Trial. Int J Dermatol Venereol. 2025;8(3):134-139. doi:10.1097/JD9.0000000000000429. Accessed October 5, 2026. https://mednexus.org/doi/full/10.1097/JD9.0000000000000429